ArticleBMC pediatrics2025
Factors associated with mortality in immunocompromised children with varicella.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- A systematic review of adverse effects associated with systemic corticosteroids in the management of leprosy.PLoS neglected tropical diseases · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCombatting vaccine-preventable disease is a core strategy to achieve universal health coverage, including varicella. In immunocompetent children, varicella is generally a benign, self-limiting disease that rarely causes complications and death, whereas in immunocompromised children, morbidity and mortality due to varicella are much higher. The aim of this study is to analyze the factors of varicella-related death in immunocompromised children at one center, Dr. Sardjito General Hospital, Indonesia.
methodsWe recorded immunocompromised pediatric patients (1 month-18 years old) diagnosed with varicella retrospectively between January 2017 and December 2022 at Dr. Sardjito General Hospital. Factors associated with mortality were tested using bivariate analysis.
resultsA total of 74 children with varicella were hospitalized during the study period. Of these patients, 63 were immunocompromised (85%). Thirty-six (57%) patients had an underlying haematological malignancy ; 11 (18%) patients had solid organ tumors; and 16 (25%) patients had non-malignant diseases. The mean age was 8.4 (± 4.65) years, with a male-to-female ratio of 1.3 to 1. The median time from the onset of the first skin rash to the administration of an intravenous acyclovir was 2 (0-8) days. None of the patients had received the varicella vaccination. Twenty patients (32%) developed one or more complications, where pneumonia accounted for the highest number of cases (12.7%). We recorded varicella-related deaths in 6 (9.5%) patients. Children who had ≥ 2 varicella complications (RR 23.64 (95%CI 3.06-182.90), p < 0.001), and with neutrophil/lymphocyte (NLR) ratio > 3.3 (RR 6.67 (95% CI 0.83-53.81); p 0.047) were associated with a significantly higher risk of death.
conclusionMultiple complications and a neutrophil/lymphocyte (NLR) ratio > 3.3 were associated with a significantly higher risk of death in immunocompromised children with varicella.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.